Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 9/20 | 0.58 |
| ▸ | TNNC1 | P63316 | 6/20 | 0.58 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.58 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.58 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.58 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.58 |
| ▸ | GPR183 | P32249 | 1/20 | 0.58 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8497906 | 0.98 | S1PR1 (0.59) | S1PR1TNNC1S1PR3S1PR4S1PR5 | |
| SCHEMBL16202272 | 0.92 | S1PR1 (0.59) | S1PR1TNNC1S1PR3S1PR4S1PR5 | |
| SCHEMBL6529404 | 0.88 | S1PR1 (0.59) | S1PR1TNNC1S1PR3S1PR4S1PR5 | |
| SCHEMBL8496127 | 0.88 | TNNC1 (0.54) | S1PR1TNNC1S1PR3S1PR4S1PR5 | |
| SCHEMBL8498023 | 0.86 | TNNC1 (0.57) | S1PR1TNNC1S1PR3S1PR4S1PR5 | |
| SCHEMBL8497060 | 0.84 | TNNC1 (0.60) | S1PR1TNNC1S1PR3S1PR4S1PR5 | |
| SCHEMBL8496561 | 0.84 | TNNC1 (0.60) | S1PR1TNNC1S1PR3S1PR4S1PR5 | |
| SCHEMBL8498534 | 0.84 | TNNC1 (0.60) | S1PR1TNNC1S1PR3S1PR4S1PR5 | |
| SCHEMBL8497058 | 0.84 | TNNC1 (0.60) | S1PR1TNNC1S1PR3S1PR4S1PR5 | |
| SCHEMBL8495964 | 0.84 | TNNC1 (0.60) | S1PR1TNNC1S1PR3S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865163-B2 | Carbon dioxide as a directing group for C—H functionalization reactions involving Lewis basic amines, alcohols, thiols, and phosphines for the synthesis of compounds | THE UNIVERSITY OF TOLEDO (US) | 2020-12-15 | — | — | US | claimed |
| US-20190185392-A1 | Carbon Dioxide as a Directing Group for C-H Functionalization Reactions Involving Lewis Basic Amines, Alcohols, Thiols, and Phosphines for the Synthesis of Compounds | THE UNIVERSITY OF TOLEDO (US) | 2019-06-20 | — | — | US | claimed |
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | GLAS USA LLC | 2022-05-05 | — | — | US | disclosed |
| US-10865163-B2 | Carbon dioxide as a directing group for C—H functionalization reactions involving Lewis basic amines, alcohols, thiols, and phosphines for the synthesis of compounds | THE UNIVERSITY OF TOLEDO (US) | 2020-12-15 | — | — | US | disclosed |
| US-20190185392-A1 | Carbon Dioxide as a Directing Group for C-H Functionalization Reactions Involving Lewis Basic Amines, Alcohols, Thiols, and Phosphines for the Synthesis of Compounds | THE UNIVERSITY OF TOLEDO (US) | 2019-06-20 | — | — | US | disclosed |
| US-20170333368-A1 | Paediatric Compositions For Treating Multiple Sclerosis | NOVARTIS AG (CH) | 2017-11-23 | — | — | US | disclosed |
| EP-2356090-B1 | CRYSTALLINE FORMS OF FINGOLIMOD HCL | NOVARTIS AG (CH) | 2017-07-05 | — | — | EP | disclosed |
| US-20170128389-A1 | Paediatric Compositions For Treating Multiple Sclerosis | NOVARTIS AG (CH) | 2017-05-11 | — | — | US | disclosed |
| US-20160206574-A1 | Paediatric Compositions For Treating Multiple Sclerosis | NOVARTIS AG (CH) | 2016-07-21 | — | — | US | disclosed |
| EP-3011958-A1 | PAEDIATRIC COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS | Novartis AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20160022611-A1 | Paediatric Compositions For Treating Multiple Sclerosis | KOVARIK JOHN M (CH) | 2016-01-28 | — | — | US | disclosed |
| US-8680146-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-03-25 | — | — | US | disclosed |
| US-20140051766-A1 | Organic Compounds | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| US-8530522-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-09-10 | — | — | US | disclosed |
| US-20130230489-A1 | Paediatric Compositions For Treating Multiple Sclerosis | KOVARIK JOHN M (CH) | 2013-09-05 | — | — | US | disclosed |
| WO-2012041359-A1 | PROCESS FOR MAKING FINGOLIMOD | SYNTHON B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041358-A1 | PROCESS FOR MAKING FINGOLIMOD HYDROCHLORIDE CRYSTALS | SYNTHON B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
| US-20070135450-A1 | Compounds and Methods of Treating Insulin Resistance and Cardiomyopathy | FORBES MEDI-TECH (RESEARCH), INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-7189748-B2 | Compounds and methods for treating insulin resistance and cardiomyopathy | FORBES MEDI-TECH (RESEARCH), INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7169817-B2 | Bis-aromatic alkanols | IRM LLC (BM) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230489-A1 | Paediatric Compositions For Treating Multiple Sclerosis | SMN1; SMN2, PMP22, MYT1 | S1PR1 22/4885TNNC1 3070/4885S1PR3 16/4885 |
| US-20160206574-A1 | Paediatric Compositions For Treating Multiple Sclerosis | SMN1; SMN2, PMP22, CFTR | S1PR1 25/4885TNNC1 2959/4885S1PR3 17/4885 |
| US-20190185392-A1 | Carbon Dioxide as a Directing Group for C-H Functionalization Reactions Involving Lewis Basic Amines, Alcohols, Thiols, and Phosphines for the Synthesis of Compounds | CHKB, HRH3, PNMT | S1PR1 1464/4885TNNC1 4419/4885S1PR3 1045/4885 |
| US-20160022611-A1 | Paediatric Compositions For Treating Multiple Sclerosis | SMN1; SMN2, PMP22, CFTR | S1PR1 25/4885TNNC1 2959/4885S1PR3 17/4885 |
| US-20140051766-A1 | Organic Compounds | SSB, HLA-DRB1, AQP4 | S1PR1 1172/4885TNNC1 4618/4885S1PR3 940/4885 |
| US-20170333368-A1 | Paediatric Compositions For Treating Multiple Sclerosis | SMN1; SMN2, PMP22, CFTR | S1PR1 25/4885TNNC1 2963/4885S1PR3 14/4885 |
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | S1PR2, S1PR1, S1PR4 | S1PR1 2/4885TNNC1 3515/4885S1PR3 5/4885 |
| US-10865163-B2 | Carbon dioxide as a directing group for C—H functionalization reactions involving Lewis basic amines, alcohols, thiols, and phosphines for the synthesis of compounds | CHKB, HRH3, PNMT | S1PR1 1616/4885TNNC1 4403/4885S1PR3 1171/4885 |
| US-20170128389-A1 | Paediatric Compositions For Treating Multiple Sclerosis | SMN1; SMN2, PMP22, CFTR | S1PR1 25/4885TNNC1 2959/4885S1PR3 17/4885 |
| US-20070135450-A1 | Compounds and Methods of Treating Insulin Resistance and Cardiomyopathy | CPT1A, CPT1B, PNLIP | S1PR1 161/4885TNNC1 49/4885S1PR3 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.